Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENALVax-2 dendritic cell vaccine + high-dose interleukin-2 and radiotherapy in metastatic renal cell carcinoma
2015-000556-14Phase 2Terminated
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Dec 2017
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of DC-VACCINE IRST-IRCCS and aldesleukin in metastatic renal cell carcinoma (mRCC), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoint: Overall response rate by immune-related response criteria (irRC). Started Dec 2017; status: terminated.
02
Drugs
DC-VACCINE IRST-IRCCSaldesleukin
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2015-000556-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000556-14.